碳酸氢钠治疗严重代谢性酸血症:BICAR-ICU与BICAR-ICU2试验的个体患者数据荟萃分析
该个体患者数据荟萃分析纳入BICAR-ICU与BICAR-ICU2两项RCT共1016例成人严重代谢性酸血症(pH≤7.20)患者,比较静脉碳酸氢钠滴定至pH≥7.30与不用碳酸氢钠。总体90天死亡率无显著差异(58.3% vs 60.6%;RR 0.96;95%CI 0.86-1.07;p=0.51),但碳酸氢钠显著减少RRT启动(34.8% vs 50.7%;RR 0.69;95%CI 0.60-0.79;p<0.001;NNT 6.3)并增加无透析天数(IRR 1.10;95%CI 1.06-1.14;p<0.001)。酸血症深度存在显著交互作用(p-for-interaction=0.006):pH≤7.10者90天死亡率降低(RR 0.80;95%CI 0.68-0.93;p=0.004),pH>7.10者无获益(RR 1.05;95%CI 0.92-1.21;p=0.47)。严重AKI状态及血清乳酸未见显著交互作用。
要点
- 总体人群(pH≤7.20)碳酸氢钠不降低90天死亡率(58.3% vs 60.6%;RR 0.96;95%CI 0.86-1.07;p=0.51)。
- 碳酸氢钠显著减少RRT启动(34.8% vs 50.7%;RR 0.69;95%CI 0.60-0.79;p<0.001;NNT 6.3)并增加无透析天数(IRR 1.10;95%CI 1.06-1.14;p<0.001)。
- 酸血症深度交互作用显著(p-for-interaction=0.006):pH≤7.10者90天死亡率降低(RR 0.80;95%CI 0.68-0.93;p=0.004)。
- pH>7.10者碳酸氢钠无死亡率获益(RR 1.05;95%CI 0.92-1.21;p=0.47)。
- 严重AKI状态(p-for-interaction=0.11)与血清乳酸(p-for-interaction=0.22)未见显著交互作用。
适用人群与场景
- 成人严重代谢性酸血症患者,pH≤7.20,来自BICAR-ICU与BICAR-ICU2两项RCT,共1016例(碳酸氢钠组509例,对照组507例)。
诊断标准与关键阈值
- 严重代谢性酸血症定义:pH≤7.20。
- 碳酸氢钠滴定目标:pH≥7.30。
- 亚组分层阈值:酸血症深度按pH≤7.10 vs >7.10;血清乳酸按<2mmol/L vs ≥2mmol/L;并分析严重AKI状态。
处置流程与药物剂量
- 静脉碳酸氢钠滴定至pH≥7.30,与不用碳酸氢钠对照;具体剂量、给药频次及疗程原文未提及。
- 对pH≤7.10的严重代谢性酸血症患者,碳酸氢钠可能降低90天死亡率(RR 0.80;95%CI 0.68-0.93;p=0.004)。
- 对pH>7.10者,碳酸氢钠无死亡率获益(RR 1.05;95%CI 0.92-1.21;p=0.47),但总体人群仍减少RRT启动。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:BICAR-ICU与BICAR-ICU2两项RCT的个体患者数据荟萃分析;样本量1016例(509例碳酸氢钠,507例对照);人群为成人严重代谢性酸血症(pH≤7.20)。
- 干预:静脉碳酸氢钠滴定至pH≥7.30;对照:不用碳酸氢钠。
- 主要终点:90天死亡率无显著差异(58.3% vs 60.6%;RR 0.96;95%CI 0.86-1.07;p=0.51)。
- 关键次要终点:RRT启动显著减少(34.8% vs 50.7%;RR 0.69;95%CI 0.60-0.79;p<0.001;NNT 6.3);无透析天数增加(IRR 1.10;95%CI 1.06-1.14;p<0.001)。
- 亚组:pH≤7.10者90天死亡率降低(RR 0.80;95%CI 0.68-0.93;p=0.004);pH>7.10者无获益(RR 1.05;95%CI 0.92-1.21;p=0.47);酸血症深度交互作用p-for-interaction=0.006。
- 严重AKI状态(p-for-interaction=0.11)与血清乳酸(p-for-interaction=0.22)无显著交互作用。
- 不良事件原文未提及。
证据类型、等级与局限
- 证据类型:两项RCT的个体患者数据荟萃分析。
- 证据等级或推荐强度原文未提及。
- 局限:原文未明确列出局限;设计上为个体患者数据荟萃分析,纳入两项RCT。
对床旁实践的改变
- 对pH≤7.20的严重代谢性酸血症患者,碳酸氢钠治疗可减少RRT启动(NNT=6.3),但总体不降低90天死亡率。
- 对pH≤7.10的最深酸血症患者,可考虑碳酸氢钠以降低90天死亡率(RR 0.80;95%CI 0.68-0.93)。
- 对pH>7.10者,碳酸氢钠无死亡率获益,不应仅以降低死亡率为目的使用。
- 严重AKI状态及血清乳酸水平未显示显著交互作用,不能据此选择或排除碳酸氢钠治疗。
指南或共识出处
- BICAR-ICU与BICAR-ICU2试验的个体患者数据荟萃分析(原文标题:Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Two randomized trials (BICAR-ICU and BICAR-ICU2) evaluated intravenous sodium bicarbonate therapy in patients with severe metabolic acidemia but yielded inconclusive results. We performed an individual patient data meta-analysis to assess its effects on 90-day mortality and renal replacement therapy (RRT) use, and search for heterogeneity of treatment effects across prespecified subgroups.
METHODS: We performed an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials, including adults with severe metabolic acidemia (pH ≤ 7.20). Patients were randomized to receive intravenous sodium bicarbonate titrated to a pH ≥ 7.30 or no sodium bicarbonate. The primary outcome was 90-day mortality. Secondary outcomes included RRT initiation and dialysis-free days. Prespecified subgroup analyses explored treatment-effect heterogeneity by acidemia depth (pH ≤ 7.10 vs. > 7.10), severe acute kidney injury (AKI) status, and serum lactate (< 2mmol/L vs. ≥2mmol/L).
RESULTS: A total of 1,016 patients was included (509 sodium bicarbonate, 507 control). Sodium bicarbonate therapy did not significantly reduce 90-day mortality compared to control (58.3% vs. 60.6%; risk ratio [RR], 0.96; 95%CI, 0.86-1.07; p = 0.51). However, it significantly reduced RRT initiation (34.8% vs. 50.7%; RR, 0.69; 95%CI, 0.60-0.79; p < 0.001, number needed to treat: 6.3) and increased dialysis-free days (incidence rate ratio, 1.10; 95%CI, 1.06-1.14; p < 0.001). A significant interaction was observed with acidemia depth (p-for-interaction = 0.006): in patients with pH ≤ 7.10, sodium bicarbonate reduced 90-day mortality (RR, 0.80; 95%CI, 0.68-0.93; p = 0.004); no benefit was seen with pH > 7.10 (RR, 1.05; 95%CI, 0.92-1.21; p = 0.47). No significant interactions were observed for severe AKI status (p-for-interaction = 0.11) nor serum lactate (p-for-interaction = 0.22).
CONCLUSIONS: Sodium bicarbonate therapy did not reduce overall 90-day mortality but decreased RRT use and suggested a mortality benefit in patients with the most profound acidemia (pH ≤ 7.10). These findings invite a reconsideration of current paradigms, suggesting timely correction of severe metabolic acidemia to avoid RRT in some patients.
参考来源
- Fosset M, Pensier J, Jabaudon M, et al. Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials. Crit Care. 2026. PMID: 42472834. doi:10.1186/s13054-026-06206-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。